• Policy
    • FAQ JLUdocs
    • FAQ JLUdata
    • Publishing in JLUdocs
    • Publishing in JLUdata
    • Publishing Contract
    • English
    • Deutsch
View Item 
  •   JLUpub Home
  • JLUdocs
  • Publikationen im Open Access gefördert durch die UB
  • View Item
  •   JLUpub Home
  • JLUdocs
  • Publikationen im Open Access gefördert durch die UB
  • View Item
  • Info
    • Policy
    • FAQ JLUdocs
    • FAQ JLUdata
    • Publishing in JLUdocs
    • Publishing in JLUdata
    • Publishing Contract
  • English 
    • English
    • Deutsch
  • Login
JavaScript is disabled for your browser. Some features of this site may not work without it.

Exhalative Breath Markers Do Not Offer for Diagnosis of Interstitial Lung Diseases: Data from the European IPF Registry (eurIPFreg) and Biobank

Thumbnail
Files in this item
10.3390_jcm8050643.pdf (1.988Mb)
Date
2019
Author
Krauss, Ekaterina
Froehler, Maike
Degen, Maria
Mahavadi, Poornima
Dartsch, Ruth C.
Korfei, Martina
Ruppert, Clemens
Seeger, Werner
Guenther, Andreas
Metadata
Show full item record
BibTeX Export
Quotable link
http://dx.doi.org/10.22029/jlupub-8984
Abstract

Background: New biomarkers are urgently needed to facilitate diagnosis in Interstitial Lung Diseases (ILD), thus reducing the need for invasive procedures, and to enable tailoring and monitoring of medical treatment.Methods: In this study we investigated if patients with idiopathic pulmonary fibrosis (IPF; n = 21), non-IPF ILDs (n = 57) and other ... lung diseases (chronic obstructive pulmonary disease (COPD) n = 24, lung cancer (LC) n = 16) as well as healthy subjects (n = 20) show relevant differences in exhaled NO (FeNO; Niox MINO), or in eicosanoid (PGE2, 8-isoprostane; enzyme-linked immunosorbent assay (ELISA)) levels as measured in exhaled breath condensates (EBC) and bronchoalveolar lavage fluids (BALF).Results: There was no significant difference in FeNO values between IPF, non-IPF ILDs and healthy subjects, although some individual patients showed highly elevated FeNO. On the basis of the FeNO signal, it was neither possible to differentiate between the kind of disease nor to detect exacerbations. In addition, there was no correlation between FeNO values and lung function. The investigation of the eicosanoids in EBCs was challenging (PGE2) or unreliable (8-isoprostane), but worked out well in BALF. A significant increase of free 8-isoprostane was observed in BALF, but not in EBCs, of patients with IPF, hypersensitivity pneumonitis (HP) and sarcoidosis, possibly indicating severity of oxidative stress.Conclusions: FeNO-measurements are not of diagnostic benefit in different ILDs including IPF. The same holds true for PGE2 and 8-isoprostane in EBC by ELISA.

URI of original publication
https://doi.org/10.3390/jcm8050643
Collections
  • Publikationen im Open Access gefördert durch die UB
Namensnennung 4.0 International
Namensnennung 4.0 International

Contact Us | Impressum | Privacy Policy | OAI-PMH
 

 

Browse

All of JLUpubCommunities & CollectionsOrganisational UnitDDC-ClassificationPublication TypeAuthorsBy Issue DateThis CollectionOrganisational UnitDDC-ClassificationPublication TypeAuthorsBy Issue Date

My Account

LoginRegister

Statistics

View Usage Statistics

Contact Us | Impressum | Privacy Policy | OAI-PMH